Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin 10 mg daily Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

NCT05342974
View directory record Official record
Conditions
Abortion Early
Interventions
Atorvastatin, Misoprostol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

NCT04369664
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Statin, PCSK9 inhibitor, Ezetimibe 10mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Actual Use Trial of Atorvastatin Calcium 10 mg

NCT01964326
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin calcium 10 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
37
States / cities
Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

NCT00814255
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

NCT01288469
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

NCT06191991
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Atorvastatin, ALG-055009, Rosuvastatin
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 7, 2026, 2:17 AM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 7, 2026, 2:17 AM EDT
Terminated Phase 3 Interventional Results available

Ezetimibe in Patients Hypo-responsive to Statins

NCT00965055
View directory record Official record
Conditions
High Cholesterol, Coronary Artery Disease
Interventions
Ezetimibe, Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 7, 2026, 2:17 AM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

NCT01288443
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
38
States / cities
Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

NCT00487994
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Atorvastatin Three Year Pediatric Study

NCT00827606
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 15 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 7, 2026, 2:17 AM EDT
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

NCT04608344
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 7, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

NCT01236365
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 7, 2026, 2:17 AM EDT